Leo Pharma As patents expiration
1. Enstilar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119781 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10688108 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10660908 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US9566286 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10716799 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10682364 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10617698 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10130640 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
|
US10130640 (Pediatric) | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Dec, 2031
(8 years from now) | |
|
US9119781 (Pediatric) | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Dec, 2031
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity (PED) | Jan 30, 2023 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient
Market Authorisation Date: 16 October, 2015
Treatment: Plaque psoriasis; Topical treatment of plaque psoriasis in patients 12 years and older
Dosage: AEROSOL, FOAM;TOPICAL
ENSTILAR family patents
2. Finacea patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8900554 | LEO PHARMA AS | Foamable composition and uses thereof |
Oct, 2023
(25 days from now) | |
| US10322085 | LEO PHARMA AS | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Oct, 2023
(25 days from now) | |
| US8722021 | LEO PHARMA AS | Foamable carriers |
Oct, 2023
(25 days from now) | |
| US8435498 | LEO PHARMA AS | Penetrating pharmaceutical foam |
Mar, 2024
(5 months from now) | |
| US7700076 | LEO PHARMA AS | Penetrating pharmaceutical foam |
Sep, 2027
(3 years from now) | |
| US10117812 | LEO PHARMA AS | Foamable composition combining a polar solvent and a hydrophobic carrier |
Oct, 2027
(4 years from now) | |
| US9265725 | LEO PHARMA AS | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Dec, 2027
(4 years from now) | |
| US9211259 | LEO PHARMA AS | Antibiotic kit and composition and uses thereof |
Feb, 2029
(5 years from now) | |
Drugs and Companies using AZELAIC ACID ingredient
Market Authorisation Date: 29 July, 2015
Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea
Dosage: AEROSOL, FOAM;TOPICAL
FINACEA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic